TB-500 Cycle Length: How Long Is a TB-500 Cycle? (2026)

There is no clinically established TB-500 cycle length. Community research references commonly describe 4–6 weeks as a shorter active period and 8–12 weeks as a longer or more complete cycle. Those ranges are community conventions, not schedules proven in controlled human trials.

The key evidence gap is specific to the molecule. TB-500 is commonly identified as the short LKKTETQ-related fragment of thymosin beta-4. Human thymosin beta-4 research has used full-length Tβ4 in other formulations, but those studies do not validate an injectable TB-500 cycle.

For dose amounts, frequency, reconstitution, vial math, and U-100 syringe calculations, use the TB-500 protocol. This page stays focused on duration, breaks, and evidence.

The table below compares the TB-500 cycle lengths most often used as community research labels. It does not add a dose or claim that one duration is better than another.

TB-500 cycle lengths come mainly from research-community protocols, older peptide guides, and schedules built around an early higher-frequency phase followed by a lower-frequency continuation phase. They do not come from a trial that assigned people to different injectable TB-500 cycle lengths.

This distinction is central to any TB-500 cycle page. FDA describes TB-500 as a thymosin beta-4 fragment and states that it has not identified human exposure data for drug products containing the thymosin beta-4 fragment known as TB-500. FDA's safety-risk page also notes important gaps in the safety information available for the fragment.

Full-length thymosin beta-4 has been studied in humans. Examples include ophthalmic RGN-259 trials lasting 28 days and a topical RGN-137 venous-stasis-ulcer study that allowed treatment for up to 84 days. Those studies establish that researchers have studied full-length Tβ4 over multi-week periods. They do not establish an injectable TB-500 cycle.

A 4-week TB-500 cycle usually means a short active research period. In some community schedules it represents the early portion of a longer cycle, while other references treat four weeks as a complete short cycle.

What it does not mean is equally important. No controlled human trial has shown that four weeks is an optimal TB-500 endpoint, and FDA says it has not identified human exposure data for drug products containing the TB-500 fragment.

Six weeks is often used as the upper end of the shorter TB-500 cycle range. It fits the 4–6 week framework already used in many community research references and can also mark the point where some longer schedules transition into a continuation phase.

There is no study showing that six weeks is safer, more effective, or more appropriate than four or eight weeks. It is better described as a common community stopping point than as an evidence-based rule.

An 8-week TB-500 cycle is one of the clearest full-cycle structures in current community references. It gives enough calendar time for an early phase and a later continuation phase without moving into the longer 12-week range.

That structure explains why eight weeks appears often in peptide guides. It does not show that eight weeks was selected from a human TB-500 dose-ranging or duration trial.

For the separate question of what community references mean by loading, tapering, dose amount, or frequency, use the TB-500 protocol.

A 12-week TB-500 cycle sits at the longer end of the community range documented on PDP. It is generally described as an extended active period or as a longer continuation after an earlier phase.

Twelve weeks can look more evidence-based because full-length thymosin beta-4 was studied topically for up to 84 days in a venous-stasis-ulcer trial. That is not a valid reason to call 12 weeks a proven injectable TB-500 cycle. The study used full-length Tβ4 as a topical gel in a specific patient population.

Community references often pair TB-500 active periods with breaks of several weeks. A 4-week break is commonly mentioned after shorter cycles, while 4–8 week breaks appear with longer schedules.

No controlled human TB-500 study has established a required off period, compared different washout lengths, or shown that a specific break resets a measurable biological response.

Human evidence does not establish that TB-500 must be used in an on-and-off cycle. Cycling is common in community protocol language, but the TB-500 fragment lacks the human trial data needed to prove that a specific cycling pattern is necessary.

This matters because community habit can easily turn into a rule. Statements such as 'TB-500 must be cycled,' 'four weeks off is required,' or '12 weeks is the maximum' should not be presented as established facts unless a study directly supports them.

The most useful published duration data come from full-length thymosin beta-4 research. These studies help show what has actually been tested in humans, but they also show why a TB-500 cycle page needs a strong evidence boundary.

A research duration becomes relevant to a cycle only when the molecule, formulation, route, population, amount, frequency, and study goal are also relevant. Here, those conditions are not met.

Cycle length and dosage answer different search questions. Keeping them separate makes the cycle page more useful and prevents it from duplicating the main protocol.

This split is intentional. The cycle page targets TB-500 cycle length, how long a TB-500 cycle lasts, off-cycle timing, and 4- to 12-week duration questions. The protocol page keeps the stronger dosage-chart, dosing, frequency, and calculator intent.

A TB-500-only cycle should not be treated as the same research question as a BPC-157 + TB-500 Wolverine Stack cycle. Adding BPC-157 changes the combination, evidence base, schedule logic, and total exposure being discussed.

The Wolverine Stack cycle guide separately covers the 4–6, 6–8, and 8–12 week schedules commonly used for the combination. This TB-500 page stays focused on the TB-500 component alone.

FDA lists the thymosin beta-4 fragment known as TB-500 among bulk substances for which the agency has identified significant information gaps and potential safety concerns. FDA specifically states that it has not identified human exposure data for drug products containing the fragment.

On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee also considered TB-500 free base and TB-500 acetate in connection with possible inclusion on the 503A Bulks List. FDA explains that advisory-committee recommendations are non-binding. A committee discussion should not be described as FDA approval of TB-500 or as validation of a cycle length.